Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.

@article{Burgdorf2015RapastinelH,
  title={Rapastinel (GLYX-13) has therapeutic potential for the treatment of post-traumatic stress disorder: Characterization of a NMDA receptor-mediated metaplasticity process in the medial prefrontal cortex of rats.},
  author={Jeffrey S. Burgdorf and Roger A. Kroes and Xiao-lei Zhang and Amanda L Gross and Mary Schmidt and Craig Weiss and John F. Disterhoft and Ronald M. Burch and Patric K. Stanton and Joseph r. Moskal},
  journal={Behavioural brain research},
  year={2015},
  volume={294},
  pages={177-85}
}
Rapastinel (GLYX-13) is a NMDA receptor modulator with glycine-site partial agonist properties. It is a robust cognitive enhancer and shows rapid and long-lasting antidepressant properties in both animal models and in humans. Contextual fear extinction (CFE) in rodents has been well characterized and used extensively as a model to study the neurobiological mechanisms of post-traumatic stress disorder (PTSD). Since CFE is NMDA receptor modulated and neural circuitry in the medial prefrontal… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
18 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Similar Papers

Loading similar papers…